Unity Biotechnology Inc (NASDAQ: UBX) is 36.21% higher on its value in year-to-date trading and has touched a low of $0.94 and a high of $2.02 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The UBX stock was last observed hovering at around $1.81 in the last trading session, with the day’s loss setting it -0.48%.
Currently trading at $1.33, the stock is 16.26% and 11.24% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.46 million and changing -26.52% at the moment leaves the stock -5.99% off its SMA200. UBX registered -30.37% loss for a year compared to 6-month loss of -8.28%. The firm has a 50-day simple moving average (SMA 50) of $1.1958 and a 200-day simple moving average (SMA200) of $1.41595.
The stock witnessed a 11.76% gain in the last 1 month and extending the period to 3 months gives it a -10.74%, and is 36.21% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 25.09% over the week and 10.07% over the month.
Unity Biotechnology Inc (UBX) has around 19 employees, a market worth around $22.41M and $0.00M in sales. Distance from 52-week low is 41.53% and -34.16% from its 52-week high. The company has generated returns on investments over the last 12 months (-62.82%).
The EPS is expected to grow by 49.70% this year
42.0 institutions hold shares in Unity Biotechnology Inc (UBX), with institutional investors hold 20.82% of the company’s shares. The shares outstanding are 16.85M, and float is at 15.37M with Short Float at 1.60%. Institutions hold 20.55% of the Float.
Unity Biotechnology Inc (UBX) Insider Activity
The most recent transaction is an insider sale by Ghosh Anirvan, the company’s Chief Executive Officer. SEC filings show that Ghosh Anirvan sold 432 shares of the company’s common stock on Nov 04 ’24 at a price of $1.29 per share for a total of $557.0. Following the sale, the insider now owns 75893.0 shares.
Unity Biotechnology Inc disclosed in a document filed with the SEC on Nov 04 ’24 that Sullivan Lynne Marie (CFO & Head of Corp. Dev.) sold a total of 136 shares of the company’s common stock. The trade occurred on Nov 04 ’24 and was made at $1.29 per share for $175.0. Following the transaction, the insider now directly holds 55925.0 shares of the UBX stock.
Still, SEC filings show that on Nov 04 ’24, Nguyen Alexander Hieu (Chief Legal Officer) disposed off 149 shares at an average price of $1.29 for $192.0. The insider now directly holds 24,723 shares of Unity Biotechnology Inc (UBX).
